Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Fulcrum Therapeutics Now Expects That Its Existing Cash And Equivalents To Be Sufficient To Fund Its Operating Requirements Into 2026, An Update To Prior Guidance Of Mid-2025

Author: Benzinga Newsdesk | November 07, 2023 08:10am

Posted In: FULC